Entities tied to SpyGlass Pharma (SGP) holder boost stake
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SpyGlass Pharma, Inc. reported insider-related equity changes involving a 10% owner on February 9, 2026. Investment entities NEA 17 and NEA 16, which are the direct beneficial owners of the securities, had multiple series of preferred stock automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering on February 9, 2026.
On the same date, an entity associated with NEA 17 indirectly purchased 937,500 shares of common stock at $16 per share. After these transactions, 6,035,038 shares of common stock were indirectly beneficially owned through NEA 17 and 1,357,263 shares through NEA 16, while the reporting person disclaims beneficial ownership of portions in which he has no pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 937,500 shares ($15,000,000)
Net Buy
13 txns
Insider
Florence Anthony A. Jr.
Role
10% Owner
Bought
937,500 shs ($15.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock | 1,619,240 | $0.00 | -- |
| Conversion | Series C-1 Preferred Stock | 1,370,168 | $0.00 | -- |
| Conversion | Series C-2 Preferred Stock | 1,370,168 | $0.00 | -- |
| Conversion | Series D Preferred Stock | 737,962 | $0.00 | -- |
| Conversion | Series A Preferred Stock | 954,990 | $0.00 | -- |
| Conversion | Series B Preferred Stock | 402,273 | $0.00 | -- |
| Conversion | Common Stock | 1,619,240 | $0.00 | -- |
| Conversion | Common Stock | 1,370,168 | $0.00 | -- |
| Conversion | Common Stock | 1,370,168 | $0.00 | -- |
| Conversion | Common Stock | 737,962 | $0.00 | -- |
| Purchase | Common Stock | 937,500 | $16.00 | $15.00M |
| Conversion | Common Stock | 954,990 | $0.00 | -- |
| Conversion | Common Stock | 402,273 | $0.00 | -- |
Holdings After Transaction:
Series B Preferred Stock — 0 shares (Indirect, See Note 2);
Series C-1 Preferred Stock — 0 shares (Indirect, See Note 2);
Series C-2 Preferred Stock — 0 shares (Indirect, See Note 2);
Series D Preferred Stock — 0 shares (Indirect, See Note 2);
Series A Preferred Stock — 0 shares (Indirect, See Note 3);
Common Stock — 1,619,240 shares (Indirect, See Note 2)
Footnotes (1)
- All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.
FAQ
What insider activity did SpyGlass Pharma (SGP) disclose in this Form 4?
SpyGlass Pharma disclosed that entities affiliated with a 10% owner converted multiple series of preferred stock into common stock and indirectly bought 937,500 common shares at $16 per share on February 9, 2026, around the company’s initial public offering.
What preferred stock conversions did SpyGlass Pharma (SGP) report for the 10% owner?
The filing reports that all shares of the issuer’s Series A, B, C-1, C-2, and D preferred stock automatically converted on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering on February 9, 2026.
What ownership disclaimer did the SpyGlass Pharma (SGP) reporting person make?
The reporting person stated he is a manager of the general partners of NEA 17 and NEA 16, but disclaims beneficial ownership under Section 16 of the Exchange Act of any portion of SpyGlass Pharma securities held by those funds in which he has no pecuniary interest.